검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Immunotherapy |
Overview Company | TheraOp |
Overview Modality | ANTIBODY |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Stage III Non-small Cell Lung Cancer; Locally Advanced |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | checkpoint implicated in ApoE-mediated suppression of amyloid-β (Aβ) clearance and inflammatory signaling, |
MoA Biomarker | PD-L1 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).. The prognosis of patients with advanced non-small cell lung cancer (NSCLC) complicated by cancer cachexia remains poor. Anamorelin, a ghrelin receptor agonist, has been approved only in Japan for the treatment of cancer cachexia. This prospective multicentre observat… |
Clinical Primary efficacy | ORR 77.7% |
Clinical ORR | 77.7% |
Clinical Result source | ClinicalTrials.gov NCT03361072 |
Clinical Data Tier / Score | A · 58 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Immunotherapy |
Overview Company | TheraOp |
Overview Modality | ANTIBODY |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Stage III Non-small Cell Lung Cancer; Locally Advanced |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | checkpoint implicated in ApoE-mediated suppression of amyloid-β (Aβ) clearance and inflammatory signaling, |
MoA Biomarker | PD-L1 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).. The prognosis of patients with advanced non-small cell lung cancer (NSCLC) complicated by cancer cachexia remains poor. Anamorelin, a ghrelin receptor agonist, has been approved only in Japan for the treatment of cancer cachexia. This prospective multicentre observat… |
Clinical Primary efficacy | ORR 77.7% |
Clinical ORR | 77.7% |
Clinical Result source | ClinicalTrials.gov NCT03361072 |
Clinical Data Tier / Score | A · 58 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교